Nicholas J Hawkins

List of Publications by Year
in descending order

96 papers	7,055 citations	76326 40 h-index	58581 82 g-index
98 all docs	98 docs citations	98 times ranked	9672 citing authors

#	Article	IF	Citations
1	Whole slide images based cancer survival prediction using attention guided deep multiple instance learning networks. Medical Image Analysis, 2020, 65, 101789.	11.6	202
2	Tumour infiltrating lymphocyte status is superior to histological grade, DNA mismatch repair and BRAF mutation for prognosis of colorectal adenocarcinomas with mucinous differentiation. Modern Pathology, 2020, 33, 1420-1432.	5.5	17
3	Scarcity of Recurrent Regulatory Driver Mutations in Colorectal Cancer Revealed by Targeted Deep Sequencing. JNCI Cancer Spectrum, 2019, 3, pkz012.	2.9	2
4	Evaluation of the transferability of survival calculators for stage II/III colon cancer across healthcare systems. International Journal of Cancer, 2019, 145, 132-142.	5.1	1
5	Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes. Gut, 2019, 68, 465-474.	12.1	52
6	Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. The Lancet Gastroenterology and Hepatology, 2018, 3, 635-643.	8.1	60
7	MACROD2 Haploinsufficiency Impairs Catalytic Activity of PARP1 and Promotes Chromosome Instability and Growth of Intestinal Tumors. Cancer Discovery, 2018, 8, 988-1005.	9.4	55
8	Disruption of a â^'35 kb Enhancer Impairs CTCF Binding and MLH1 Expression in Colorectal Cells. Clinical Cancer Research, 2018, 24, 4602-4611.	7.0	12
9	The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study. Oncologist, 2016, 21, 618-625.	3.7	12
10	Integrated Genetic, Epigenetic, and Transcriptional Profiling Identifies Molecular Pathways in the Development of Laterally Spreading Tumors. Molecular Cancer Research, 2016, 14, 1217-1228.	3.4	20
11	Pathogenic germline MCM9 variants are rare in Australian Lynch-like syndrome patients. Cancer Genetics, 2016, 209, 497-500.	0.4	8
12	ROR2 is epigenetically inactivated in the early stages of colorectal neoplasia and is associated with proliferation and migration. BMC Cancer, 2016, 16, 508.	2.6	29
13	SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing MGMT-Methylated Colorectal Cancer. Clinical Cancer Research, 2016, 22, 6266-6277.	7.0	22
14	Relative telomere lengths in tumor and normal mucosa are related to disease progression and chromosome instability profiles in colorectal cancer. Oncotarget, 2016, 7, 36474-36488.	1.8	23
15	Integration and Analysis of Heterogeneous Colorectal Cancer Data for Translational Research. Studies in Health Technology and Informatics, 2016, 225, 387-91.	0.3	1
16	Single nucleotide polymorphism array profiling identifies distinct chromosomal aberration patterns across colorectal adenomas and carcinomas. Genes Chromosomes and Cancer, 2015, 54, 303-314.	2.8	14
17	Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both Î²-catenin dependent and independent Wnt signalling. Journal of Cancer Research and Clinical Oncology, 2015, 141, 243-254.	2.5	58
18	Institutional biobanking: an integral part of contemporary pathology practice. Pathology, 2015, 47, 4-6.	0.6	2

#	Article	IF	Citations
19	Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer. British Journal of Cancer, 2015, 113, 979-988.	6.4	35
20	Adaptive Tutorials Versus Web-Based Resources in Radiology: A Mixed Methods Comparison of Efficacy and Student Engagement. Academic Radiology, 2015, 22, 1299-1307.	2.5	28
21	Epigenetic inactivation of the candidate tumor suppressorUSP44is a frequent and early event in colorectal neoplasia. Epigenetics, 2014, 9, 1092-1100.	2.7	42
22	Altered promoter nucleosome positioning is an early event in gene silencing. Epigenetics, 2014, 9, 1422-1430.	2.7	25
23	Introducing Research Initiatives into Healthcare: What Do Doctors Think?. Biopreservation and Biobanking, 2014, 12, 91-98.	1.0	14
24	Cohesin Rad21 Mediates Loss of Heterozygosity and Is Upregulated via Wnt Promoting Transcriptional Dysregulation in Gastrointestinal Tumors. Cell Reports, 2014, 9, 1781-1797.	6.4	40
25	Tolerance of Whole-Genome Doubling Propagates Chromosomal Instability and Accelerates Cancer Genome Evolution. Cancer Discovery, 2014, 4, 175-185.	9.4	359
26	RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas. British Journal of Cancer, 2014, 110, 1606-1613.	6.4	50
27	SMAD2, SMAD3 and SMAD4 Mutations in Colorectal Cancer. Cancer Research, 2013, 73, 725-735.	0.9	260
28	Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. American Journal of Gastroenterology, 2013, 108, 1785-1793.	0.4	120
29	Prohibitin expression is associated with high grade breast cancer but is not a driver of amplification at 17q21.33. Pathology, 2013, 45, 629-636.	0.6	10
30	Population-Based Molecular Screening for Lynch Syndrome: Implications for Personalized Medicine. Journal of Clinical Oncology, 2013, 31, 2554-2562.	1.6	76
31	PIK3CA and PTEN Gene and Exon Mutation-Specific Clinicopathologic and Molecular Associations in Colorectal Cancer. Clinical Cancer Research, 2013, 19, 3285-3296.	7.0	107
32	Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/Î²-catenin signalling thresholds for tumourigenesis. Oncogene, 2013, 32, 4675-4682.	5.9	117
33	A correlation of the endoscopic characteristics of colonic laterally spreading tumours with genetic alterations. European Journal of Gastroenterology and Hepatology, 2013, 25, 319-326.	1.6	9
34	Relative Distribution of Folate Species Is Associated with Global DNA Methylation in Human Colorectal Mucosa. Cancer Prevention Research, 2012, 5, 921-929.	1.5	19
35	Abstract 3125: Relative distribution of folate species is associated with global DNA methylation in human colorectal mucosa. , 2012, , .		18
36	Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma. Pathology, 2011, 43, 84-85.	0.6	7

#	Article	IF	Citations
37	Methylation of the 3p22 region encompassing MLH1 is representative of the CpG island methylator phenotype in colorectal cancer. Modern Pathology, 2011, 24, 396-411.	5.5	39
38	Detection of allelic imbalance in MLH1 expression by pyrosequencing serves as a tool for the identification of germline defects in Lynch syndrome. Familial Cancer, 2010, 9, 345-356.	1.9	14
39	Implementation of Novel Pyrosequencing Assays to Screen for Common Mutations of BRAF and KRAS in a Cohort of Sporadic Colorectal Cancers. Diagnostic Molecular Pathology, 2009, 18, 62-71.	2.1	48
40	MGMT methylation is associated primarily with the germline C>T SNP (rs16906252) in colorectal cancer and normal colonic mucosa. Modern Pathology, 2009, 22, 1588-1599.	5.5	64
41	Serrated and non-serrated polyps of the colorectum: their prevalence in an unselected case series and correlation of BRAF mutation analysis with the diagnosis of sessile serrated adenoma. Journal of Clinical Pathology, 2009, 62, 516-518.	2.0	180
42	Poor-Prognosis Estrogen Receptorâ€“Positive Breast Cancer Identified by Histopathologic Subclassification. Clinical Cancer Research, 2008, 14, 6625-6633.	7.0	13
43	Epigenetic Inactivation of a Cluster of Genes Flanking MLH1 in Microsatellite-Unstable Colorectal Cancer. Cancer Research, 2007, 67, 9107-9116.	0.9	63
44	Colorectal cancer: a model for epigenetic tumorigenesis. Gut, 2007, 56, 140-148.	12.1	146
45	Inheritance of a Cancer-AssociatedMLH1Germ-Line Epimutation. New England Journal of Medicine, 2007, 356, 697-705.	27.0	380
46	The collagenase-1 (MMP-1) gene promoter polymorphism - 1607/2G is associated with favourable prognosis in patients with colorectal cancer. British Journal of Cancer, 2007, 96, 783-792.	6.4	50
47	Factors Influencing the Detection of Mutant K-ras in the Serum of Patients with Colorectal Cancer. Annals of the New York Academy of Sciences, 2006, 906, 17-18.	3.8	3
48	Germline epimutations of APC are not associated with inherited colorectal polyposis. Gut, 2006, 55, 586-587.	12.1	10
49	The role of MYH and microsatellite instability in the development of sporadic colorectal cancer. British Journal of Cancer, 2006, 95, 1239-1243.	6.4	47
50	Routine testing for mismatch repair deficiency in sporadic colorectal cancer is justified. Journal of Pathology, 2005, 207, 377-384.	4.5	49
51	MLH1 Germline Epimutations as a Factor in Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology, 2005, 129, 1392-1399.	1.3	179
52	The CpG Island Methylator Phenotype Is Not Associated with a Personal or Family History of Cancer. Cancer Research, 2004, 64, 7618-7621.	0.9	27
53	Inactivation ofp16INK4a by CpG hypermethylation is not a frequent event in colorectal cancer. Journal of Surgical Oncology, 2003, 84, 143-150.	1.7	18
54	Re: Tomlinsonet al. Does MSI-low exist.J Pathol 2002; 197: 6-13. Journal of Pathology, 2003, 199, 267-269.	4.5	5

#	Article	IF	Citations
55	Histopathological and Clinical Evaluation of Serrated Adenomas of the Colon and Rectum. Modern Pathology, 2003, 16, 417-423.	5.5	74
56	The Relationship between Hypomethylation and CpG Island Methylation in Colorectal Neoplasia. American Journal of Pathology, 2003, 162, 1361-1371.	3.8	165
57	CD103+ intraepithelial lymphocytesâ€"a unique population in microsatellite unstable sporadic colorectal cancer. European Journal of Cancer, 2003, 39, 469-475.	2.8	74
58	Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 3410-3415.	7.1	425
59	Adverse Prognostic Effect of Methylation in Colorectal Cancer Is Reversed by Microsatellite Instability. Journal of Clinical Oncology, 2003, 21, 3729-3736.	1.6	178
60	The null oncogene hypothesis and protection from cancer. Journal of Medical Genetics, 2002, 39, 12-14.	3.2	5
61	Editorial: progress in gastrointestinal pathology in the genetic era. Pathology, 2002, 34, 493.	0.6	29
62	c-kit mutations in gastrointestinal stromal tumours. Pathology, 2002, 34, 315-319.	0.6	19
63	CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology, 2002, 122, 1376-1387.	1.3	338
64	Impact of microsatellite testing and mismatch repair protein expression on the clinical interpretation of genetic testing in hereditary non-polyposis colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2002, 128, 403-411.	2.5	27
65	The Role of hMLH1 Methylation in the Development of Synchronous Sporadic Colorectal Carcinomas. Diseases of the Colon and Rectum, 2002, 45, 674-680.	1.3	26
66	Does MSI-low exist?. Journal of Pathology, 2002, 197, 6-13.	4.5	95
67	Low-level microsatellite instability occurs in most colorectal cancers and is a nonrandomly distributed quantitative trait. Cancer Research, 2002, 62, 53-7.	0.9	79
68	The serrated neoplasia pathway. Pathology, 2002, 34, 548-55.	0.6	58
69	Kirsten ras mutations in patients with colorectal cancer: the â€˜RASCAL IIâ€™ study. British Journal of Cancer, 2001, 85, 692-696.	6.4	790
70	Biological Significance of Microsatellite Instability-Low (MSI-L) Status in Colorectal Tumors. American Journal of Pathology, 2001, 158, 779-781.	3.8	23
71	Checking the scoreboard: the impact of cancer genetics on clinical practice. Internal Medicine Journal, 2001, 31, 249-253.	0.8	1
72	Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut, 2001, 48, 821-829.	12.1	308

#	Article	IF	Citations
73	Sporadic Colorectal Cancers With Microsatellite Instability and Their Possible Origin in Hyperplastic Polyps and Serrated Adenomas. Journal of the National Cancer Institute, 2001, 93, 1307-1313.	6.3	318
74	Microsatellite-stable diploid carcinoma: a biologically distinct and aggressive subset of sporadic colorectal cancer. British Journal of Cancer, 2001, 84, 232-236.	6.4	65
75	Detection of Rare Mutant Alleles by Restriction Endonuclease-mediated Selective-PCR: Assay Design and Optimization. Clinical Chemistry, 2000, 46, 620-624.	3.2	30
76	Colorectal Carcinomas Arising in the Hyperplastic Polyposis Syndrome Progress through the Chromosomal Instability Pathway. American Journal of Pathology, 2000, 157, 385-392.	3.8	65
77	Biodistribution of filamentous phage-Fab in nude mice. Journal of Immunological Methods, 1999, 225, 171-178.	1.4	42
78	Selectable in-vivo recombination to increase antibody library size â€" an improved phage display vector system. Gene, 1999, 227, 49-54.	2.2	12
79	Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer. Human Immunology, 1999, 60, 510-515.	2.4	64
80	Restriction Endonuclease-Mediated Selective Polymerase Chain Reaction. American Journal of Pathology, 1998, 153, 373-379.	3.8	79
81	Pathological and Genetic Correlates of Apoptosis in the Progression of Colorectal Neoplasia. Tumor Biology, 1997, 18, 146-156.	1.8	34
82	The Images of Disease Project: a computer-based aid to the teaching of pathology. Medical Teacher, 1997, 19, 45-50.	1.8	4
83	Detection of K-raspoint mutation by enriched PCRâ€"colorimetric plate assay. Molecular and Cellular Probes, 1997, 11, 33-38.	2.1	21
84	Evaluation of different lymphoid tissue sources for the construction of human immunoglobulin gene libraries. Immunotechnology: an International Journal of Immunological Engineering, 1997, 3, 195-203.	2.4	27
85	Regulation and expression of human Fabs under the control of the Escherichia coli arabinose promoter, PBAD. Immunotechnology: an International Journal of Immunological Engineering, 1997, 3, 217-226.	2.4	11
86	Unconjugated antibodies for cancer therapy: lessons from the clinic. Cancer Treatment Reviews, 1997, 23, 305-319.	7.7	8
87	Developmentally-regulated expression of murine K-ras isoforms. Oncogene, 1997, 15, 1781-1786.	5.9	79
88	Isolation of human anti-c-erb B-2 Fabs from a lymph node-derived phage display library. Clinical and Experimental Immunology, 1997, 109, 166-174.	2.6	32
89	Activation of the K-ras oncogene in colorectal neoplasms is Associated with decreased apoptosis. , 1997, 79, 1106-1113.		66
90	Activation of the Kâ€ras oncogene in colorectal neoplasms is Associated with decreased apoptosis. Cancer, 1997, 79, 1106-1113.	4.1	5

#	Article	IF	Citations
91	Biological Properties of Renal Oncocytoma Cells in Culture. Urologia Internationalis, 1996, 56, 69-74.	1.3	1
92	Retrieval of human antibodies from phage-display libraries using enzymatic cleavage. Journal of Immunological Methods, 1996, 189, 73-82.	1.4	58
93	Characterisation and clinicopathological correlates of serum anti-p53 antibodies in breast and colon cancer. Journal of Cancer Research and Clinical Oncology, 1996, 122, 757-762.	2.5	26
94	Cytokine-Mediated Induction of HLA Antigen Expression on Human Glomerular Mesangial Cells. Cellular Immunology, 1994, 155, 493-500.	3.0	5
95	Recombinant antibodies: back to the future. Australian and New Zealand Journal of Medicine, 1993, 23, 393-402.	0.5	0
96	The role of mesangial cells in glomerular pathology. Pathology, 1990, 22, 24-32.	0.6	27